Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Sarcoma × eribulin × Clear all

Phase

Status

Completed 9 Recruiting 2 Withdrawn 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 Triple Negative Breast Neoplasms 4 Neoplasm Metastasis 3 Inflammatory Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma 1 Liposarcoma 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HR+HER2- Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

Radiotherapy 9 Nivolumab 9 pembrolizumab 8 Magnetic Resonance Spectroscopy 8 Doxorubicin 8 Specimen Handling 7 X-Rays 6 Cyclophosphamide 6 Biopsy 6 Phantoms, Imaging 5 Ipilimumab 5 talimogene laherparepvec 4 Radiation 4 Nuclear Medicine Department, Hospital 4 selpercatinib 3 pazopanib 3 palbociclib 3 cabozantinib 3 Sirolimus 3 Ifosfamide 3 Bevacizumab 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 olaparib 2 liposomal doxorubicin 2 larotrectinib 2 ivosidenib 2 entrectinib 2 ensartinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06263231 2025-07-29

INVINCIBLE-3

Intensity Therapeutics, Inc.

Phase 3 Active not recruiting

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡